Skip to content

Autologous Nanofat Grafting by Injection Versus With Microneedling in Post-burn and Traumatic Atrophic Scars

Autologous Nanofat Grafting by Injection Versus With Microneedling in Post-burn and Traumatic Atrophic Scars

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06566300
Enrollment
30
Registered
2024-08-22
Start date
2024-11-01
Completion date
2025-02-28
Last updated
2024-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scars

Brief summary

This study aims to evaluate the efficiency autologous nanofat injection versus autologous nanofat delivered by microneedling in management of post burn atrophic and traumatic scars.

Interventions

PROCEDUREinjection of autologous nanofat grafting

Injection of nanfat graft

PROCEDUREmicroneedling with autologus nanofat graft

delivery of nanofat graft with microneedling

Sponsors

Alexandria University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

To evaluate the efficiency autologous nanofat injection versus autologous nanofat delivered by microneedling in management of post burn atrophic and traumatic scars.

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* 1\. Males and females between 18-60 years old. 2. Post-burn or traumatic atrophic scar \> 6 months duration (16). 3. Patients not receiving any treatments for the scar within the past 3 months.

Exclusion criteria

* 1\. Patients with contractures, hypertrophic and keloid scars. 2. Patients with history of bleeding disorders or coagulopathy, or on anticoagulant therpy. 3\. Diabetes and other systemic diseases that may be complicated by the procedure. 4\. Pregnant and lactating females. 5. BMI less than 18.5 6. Patients with scars at the donor site

Design outcomes

Primary

MeasureTime frameDescription
change in the scar by by the patient and observer scar assessment scale (POSAS).6 months after the proceedurepatient and observer scar assessment scale score will be uesd

Countries

Egypt

Contacts

Primary ContactDalia I Halwag, PhD, MD
daliahalwag@gmail.com0201224489473

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026